Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a randomized controlled trial.

To evaluate the effects of early start (ES) and delayed start (DS) of GA40 over 3 years.

Why It Was Studied

Patients completing the PC phase were invited to an open-label (OL) extension.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

ES ( n = 943) patients received GA40 throughout; DS ( n = 461) patients received placebo during the PC phase and GA40 during the OL phase.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

As a double-blind Glatiramer Acetate study, the assignments were hidden from both participants and investigators until the end.

Nothing was hidden in this open-label Glatiramer Acetate study: the participants and staff both knew the treatment.

Some participants received a placebo instead of Glatiramer Acetate, giving a reference point.

Relapse, MRI, disease progression, and safety were evaluated.

What Was Measured

The subject headings attached to it are Disease Progression, Glatiramer Acetate, Immunosuppressive Agents, Magnetic Resonance Imaging, Multiple Sclerosis, Relapsing-Remitting, Outcome Assessment, Health Care and Recurrence.

The authors tagged it with the keywords annualized relapse rate, low-frequency regimen, relapsing–remitting multiple sclerosis and safety.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Glatiramer Acetate in people with multiple sclerosis.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Multiple sclerosis (Houndmills, Basingstoke, England)), a journal based in England.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.